Veradigm (MDRX) 10-Q 4 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		180,611,892

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 82,714	$ 95,607
Restricted cash	6,400	1,003
Accounts receivable, net of allowance of $37,618 and $32,670 as of June 30, 2017 and December 31, 2016, respectively	420,116	405,172
Prepaid expenses and other current assets	113,563	102,551
Total current assets	622,793	604,333
Available for sale marketable securities	63,450	149,100
Fixed assets, net	160,470	148,810
Software development costs, net	192,920	163,879
Intangible assets, net	698,950	741,403
Goodwill	1,929,283	1,924,052
Deferred taxes, net	3,451	2,791
Other assets	112,738	97,791
Total assets	3,784,055	3,832,159
Current liabilities:
Accounts payable	114,725	126,144
Accrued expenses	77,375	86,135
Accrued compensation and benefits	59,255	64,291
Deferred revenue	388,647	363,772
Current maturities of long-term debt	21,413	15,158
Current maturities of non-recourse long-term debt - Netsmart	2,460	2,451
Current maturities of capital lease obligations	8,573	9,126
Total current liabilities	672,448	667,077
Long-term debt	730,028	717,853
Non-recourse long-term debt - Netsmart	576,427	576,918
Long-term capital lease obligations	7,628	9,877
Deferred revenue	18,871	18,009
Deferred taxes, net	137,252	141,752
Other liabilities	66,302	39,787
Total liabilities	2,208,956	2,171,273
Redeemable convertible non-controlling interest - Netsmart	409,610	387,685
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of June 30, 2017 and December 31, 2016	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of June 30, 2017 and December 31, 2016; 269,116 and 180,612 shares issued and outstanding as of June 30, 2017, respectively; 267,997 and 180,510 shares issued and outstanding as of December 31, 2016, respectively	2,691	2,680
Treasury stock: at cost, 88,504 and 87,487 shares as of June 30, 2017 and December 31, 2016, respectively	(322,735)	(310,993)
Additional paid-in capital	1,784,247	1,789,959
Accumulated deficit	(337,303)	(187,351)
Accumulated other comprehensive loss	(2,335)	(61,829)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,124,565	1,232,466
Non-controlling interest	40,924	40,735
Total stockholders’ equity	1,165,489	1,273,201
Total liabilities and stockholders’ equity	$ 3,784,055	$ 3,832,159

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 37,618	$ 32,670
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	269,116,000	267,997,000
Common stock, shares outstanding	180,612,000	180,510,000
Treasury stock at cost, shares	88,504,000	87,487,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Software delivery, support and maintenance	$ 279,272	$ 249,871	$ 551,730	$ 479,029
Client services	146,819	136,650	287,836	253,050
Total revenue	426,091	386,521	839,566	732,079
Cost of revenue:
Software delivery, support and maintenance	89,071	79,154	172,468	154,323
Client services	122,229	118,683	247,168	219,542
Amortization of software development and acquisition-related assets	27,300	22,000	53,787	39,632
Total cost of revenue	238,600	219,837	473,423	413,497
Gross profit	187,491	166,684	366,143	318,582
Selling, general and administrative expenses	112,037	94,802	222,882	178,955
Research and development	46,459	47,891	95,691	94,928
Asset impairment charges	0	0	0	4,650
Amortization of intangible and acquisition-related assets	7,891	5,417	15,203	9,579
Income from operations	21,104	18,574	32,367	30,470
Interest expense	(20,290)	(16,421)	(40,470)	(23,390)
Other (loss) income, net	(214)	106	25	472
Impairment of long-term investments	(144,590)	0	(144,590)	0
Equity in net (loss) income of unconsolidated investments	(28)	(4,898)	257	(7,501)
(Loss) income before income taxes	(144,018)	(2,639)	(152,411)	51
Income tax benefit (provision)	1,007	503	835	(60)
Net loss	(143,011)	(2,136)	(151,576)	(9)
Less: Net loss (income) attributable to non-controlling interests	264	87	(189)	9
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,963)	(8,153)	(21,925)	(8,153)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (153,710)	$ (10,202)	$ (173,690)	$ (8,153)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.85)	$ (0.05)	$ (0.96)	$ (0.04)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.85)	$ (0.05)	$ (0.96)	$ (0.04)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (143,011)	$ (2,136)	$ (151,576)	$ (9)
Other comprehensive income (loss):
Foreign currency translation adjustments	832	(943)	2,347	(199)
Change in unrealized gain (loss) on available for sale securities	131,213	(18,115)	56,511	(18,115)
Change in fair value of derivatives qualifying as cash flow hedges	(315)	(227)	1,033	214
Other comprehensive income (loss) before income tax benefit (expense)	131,730	(19,285)	59,891	(18,100)
Income tax benefit (expense) related to items in other comprehensive loss	124	89	(397)	(85)
Total other comprehensive income (loss)	131,854	(19,196)	59,494	(18,185)
Comprehensive loss	(11,157)	(21,332)	(92,082)	(18,194)
Less: Comprehensive loss (income) attributable to non-controlling interests	264	87	(189)	9
Comprehensive loss, net	$ (10,893)	$ (21,245)	$ (92,271)	$ (18,185)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (151,576)	$ (9)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	101,297	76,576
Stock-based compensation expense	18,461	20,057
Excess tax benefits from stock-based compensation	0	(962)
Deferred taxes	(4,659)	(1,560)
Asset impairment charges	0	4,650
Impairment of long-term investments	144,590	0
Equity in net (income) loss of unconsolidated investments	(257)	7,501
Other losses, net	2,294	963
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(13,047)	(12,407)
Prepaid expenses and other assets	(9,231)	2,923
Accounts payable	(2,830)	15,751
Accrued expenses	(5,187)	(8,709)
Accrued compensation and benefits	(2,102)	(11,404)
Deferred revenue	24,923	37,623
Other liabilities	6,683	1,106
Net cash provided by operating activities	109,359	132,099
Cash flows from investing activities:
Capital expenditures	(25,035)	(16,632)
Capitalized software	(71,582)	(37,106)
Cash paid for business acquisitions, net of cash acquired	(3,975)	(905,540)
Purchases of equity securities, other investments and related intangible assets	(1,323)	(20,685)
Proceeds received from sale of fixed assets	0	37
Net cash used in investing activities	(101,915)	(979,926)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	0	5
Proceeds from issuance of redeemable convertible preferred stock - Netsmart	0	333,605
Excess tax benefits from stock-based compensation	0	962
Taxes paid related to net share settlement of equity awards	(6,554)	(7,363)
Payments of capital lease obligations	(5,966)	(1,638)
Credit facility payments	(110,939)	(51,362)
Credit facility borrowings, net of issuance costs	120,000	599,135
Repurchase of common stock	(12,077)	(52,075)
Net cash (used in) provided by financing activities	(15,536)	821,269
Effect of exchange rate changes on cash and cash equivalents	596	340
Net decrease in cash and cash equivalents	(7,496)	(26,218)
Cash, cash equivalents and restricted cash, beginning of period	96,610	116,873
Cash, cash equivalents and restricted cash, end of period	$ 89,114	$ 90,655

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2017 and 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have decided to adopt the standard effective January 1, 2018 using the modified retrospective method. We have completed our assessment of our systems, available data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Through evaluation of the standard’s requirements, the Company plans to utilize several practical expedients including (i) viewing shipping and handling as a fulfillment cost versus a distinct performance obligation, and (ii) the right to invoice expedient as it relates to reimbursable expenses and transaction-related revenue activities. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscription contracts that include both software licenses and software support and maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue license recognition treatment required under the new standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Business Combinations	2. Business Combinations 2017 Business Combinations Asset Purchase Agreement with Third Party On March 31, 2017, Netsmart (as defined below) entered into an Asset Purchase Agreement with a third party, for an aggregate cash consideration of $4.0 million, to acquire intellectual property, certain contractual relationships and certain associates. This transaction has been accounted for as a business combination. The Asset Purchase Agreement provides for contingent consideration to be paid to the third party based on the number of customers of the third party that migrate to Netsmart’s electronic health record product. The value of the contingent consideration has been estimated to be $0.7 million. Netsmart accrued $0.5 million at June 30, 2017 within other liabilities. This amount represents the discounted fair value of the contingent consideration. This transaction resulted in the recognition of goodwill of $4.4 million. The allocation of the fair value of the consideration transferred is based on management’s judgment after evaluating several factors, including a preliminary valuation assessment. 2016 Business Combinations Update Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”), to form a joint business entity to which we contributed our Homecare TM TM As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare TM business within Netsmart over the next five years, at which time the restriction on any unused funds will lapse. As of June 30, 2017, there is $12.8 million remaining in the escrow account. Acquisition of HealthMEDX On October 27, 2016, Netsmart completed the acquisition of HealthMEDX, LLC, a Delaware limited liability company (“HealthMEDX”), for an aggregate consideration of $39.2 million. HealthMEDX is a provider of electronic medical record solutions for long-term and post-acute care including continuing care retirement communities, assisted living, independent living, skilled nursing and home care providers. During the three months ended March 31, 2017, we finalized the allocation of the fair value of the consideration transferred and recorded a measurement period adjustment of $0.1 million related to the fair value of liabilities with an offset to goodwill. Third Party Acquisitions During the three months ended June 30, 2017, we recorded final measurement period adjustments against goodwill related to the Company’s acquisitions of third parties during the fourth quarter of 2016. Supplemental Information The supplemental pro forma results below for the three and six months ended June 30, 2016 were calculated after applying our accounting policies and adjusting the results of Netsmart and HealthMEDX to reflect (i) the additional depreciation and amortization that would have resulted from the fair value adjustments to property, plant and equipment and intangible assets, (ii) the additional interest expense associated with Netsmart’s borrowings under new term loans and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value, that would have been recognized assuming both acquisitions occurred on January 1, 2015, together with the consequential tax effects. The supplemental pro forma results were also adjusted to exclude acquisition-related and transaction costs incurred during the below periods. The effects of transactions between Allscripts and Netsmart during the periods presented have been eliminated in the supplemental pro forma data. The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three and six months ended June 30, 2016. The consolidated statements of operations for the three and six months ended June 30, 2016 do not include any actual revenue and earnings from HealthMEDX since this acquisition was completed on October 27, 2016. The below supplemental pro forma data for the combined entity is presented under the assumption that both of these acquisitions occurred on January 1, 2015: (In thousands, except per share amounts) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 44,233 $ 44,233 Net loss $ (7,113 ) $ (7,113 ) Supplemental pro forma data for combined entity: Revenue $ 403,368 $ 804,702 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (45,494 ) $ (60,490 ) Loss per share, basic and diluted $ (0.24 ) $ (0.32 )

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	3. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 financial instruments include our investment in NantHealth, Inc. (“NantHealth”) common stock. Refer to Note 11, “Other Comprehensive Income,” Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Our Level 3 financial instruments also include a third party non-marketable convertible note. The sensitivity of changes in the unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet June 30, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 63,450 $ 0 $ 0 $ 63,450 $ 149,100 $ 0 $ 0 $ 149,100 Non-marketable convertible note Other assets 0 0 1,152 1,152 0 0 1,156 1,156 1.25% Call Option Other assets 0 0 32,046 32,046 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (32,931 ) (32,931 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 2,054 0 2,054 0 1,021 0 1,021 Total $ 63,450 $ 2,054 $ 267 $ 65,771 $ 149,100 $ 1,021 $ 577 $ 150,698 Long-term Investments The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at June 30, 2017 Investment June 30, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 3,693 $ 2,436 Cost method investments 6 31,284 25,284 26,041 Total equity investments 9 $ 32,942 $ 28,977 $ 28,477 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of June 30, 2017, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Impairment of Long- term Investments As of June 30, 2017, management assessed each of our investments on an individual basis to determine if the decline in fair value was other than temporary. Based on management's assessment of each individual investment, the Company determined that the decline in fair value of certain of these investments was other than temporary based on a number of factors, including, but not limited to, uncertainty regarding our intent to hold these investments for a period of time that would be sufficient to recover our cost basis in the event of a market recovery, the fact that the fair value of each investment had continued to decline below cost over the period held, and the Company's uncertainty around the near-term prospects for certain of the investments. The cost basis of these marketable securities prior to recognizing the impairment charges was approximately $205.6 million. The Company determined the fair value of these securities based on Level 1 inputs. The aggregate carrying value of this equity investment prior to recognizing the impairment charge was $2.1 million. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as June 30, 2017, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and six months ended June 30, 2017 and 2016 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the three and six months periods ended June 30, 2017 and 2016 include stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2017 and 2016. Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 988 $ 1,061 $ 2,113 $ 2,230 Client services 993 1,138 2,565 2,628 Total cost of revenue 1,981 2,199 4,678 4,858 Selling, general and administrative expenses 7,050 6,342 10,600 11,508 Research and development 2,120 2,119 4,709 4,695 Total stock-based compensation expense $ 11,151 $ 10,660 $ 19,987 $ 21,061 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and six months ended June 30, 2017 and 2016. We granted stock-based awards as follows: Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 128 $ 11.93 1,897 $ 12.38 Performance-based restricted stock units with a service condition 0 $ 0.00 572 $ 11.93 Market-based restricted stock units with a service condition 41 $ 12.49 613 $ 13.34 169 $ 12.06 3,082 $ 12.48 During the six months ended June 30, 2017 and the year ended December 31, 2016, 1.1 million and 1.5 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the six months ended June 30, 2017 and year ended December 31, 2016 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the six months ended June 30, 2017 and 2016 were 552 thousand and 564 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On November 17, 2016, we announced that our Board approved a new stock purchase program under which we may repurchase up to $200 million of our common stock through December 31, 2019. During the three and six months ended June 30, 2017, we repurchased 1.0 million shares of our common stock under the new program for a total of $12.1 million. Netsmart Stock-based Compensation Expense Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 10 $ 25 $ (25 ) $ 25 Client services 13 37 (68 ) 37 Total cost of revenue 23 62 (93 ) 62 Selling, general and administrative expenses 478 1,328 (2,859 ) 1,328 Research and development 15 36 (76 ) 36 Total stock-based compensation expense (benefit) $ 516 $ 1,426 $ (3,028 ) $ 1,426 At June 30, 2017, the liability for outstanding awards was $2.8 No option unit awards were granted by Netsmart during the three and six months ended June 30, 2017.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2017 2016 2017 2016 Basic Loss per Common Share: Net loss $ (143,011 ) $ (2,136 ) $ (151,576 ) $ (9 ) Less: Net loss (income) attributable to non-controlling interests 264 87 (189 ) 9 Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,963 ) (8,153 ) (21,925 ) (8,153 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (153,710 ) $ (10,202 ) $ (173,690 ) $ (8,153 ) Weighted-average common shares outstanding 181,193 186,792 180,981 187,676 Basic Loss per Common Share $ (0.85 ) $ (0.05 ) $ (0.96 ) $ (0.04 ) Diluted Loss per Common Share: Net loss $ (143,011 ) $ (2,136 ) $ (151,576 ) $ (9 ) Less: Net loss (income) attributable to non-controlling interests 264 87 (189 ) 9 Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,963 ) (8,153 ) (21,925 ) (8,153 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (153,710 ) $ (10,202 ) $ (173,690 ) $ (8,153 ) Weighted-average common shares outstanding 181,193 186,792 180,981 187,676 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 181,193 186,792 180,981 187,676 Diluted Loss per Common Share $ (0.85 ) $ (0.05 ) $ (0.96 ) $ (0.04 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three and six months ended June 30, 2017 and 2016, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,652 25,210 26,668 25,227

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: June 30, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 628,082 $ (375,531 ) $ 252,551 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 813,643 (446,244 ) 367,399 813,021 (430,960 ) 382,061 Total $ 1,441,725 $ (821,775 ) $ 619,950 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,929,283 1,924,052 Total $ 2,008,283 $ 2,003,052 Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 Other additions 40 47 4,503 4,590 Foreign exchange translation 641 0 0 641 Balance as of June 30, 2017 $ 844,518 $ 404,922 $ 679,843 $ 1,929,283 There were no accumulated impairment losses associated with our goodwill as of June 30, 2017 or December 31, 2016. Other additions during the six months ended June 30, 2017 relate to goodwill arising from Netsmart’s Purchase Agreement with a third party and measurement period adjustments against goodwill related to the Company’s acquisitions of third parties. Refer to Note 2, “Business Combinations,” for additional information regarding these transactions.

Asset and Long-term Investment

Asset and Long-term Investment Impairment Charges	6 Months Ended
	Jun. 30, 2017
Asset And Long Term Investment Impairment Charges [Abstract]
Asset and Long-term Investment Impairment Charges	7. Asset and Long-term Investment Impairment Charges We incurred the following asset and long-term investment impairment charges: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Asset impairment charges $ 0 $ 0 $ 0 $ 4,650 Impairment of long-term investments $ 144,590 $ 0 $ 144,590 $ 0 During the first quarter of 2016, we incurred non-cash asset impairment charges which included $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. During the three months ended June 30, 2017, we recognized other-than-temporary non-cash impairment charges of $144.6 million associated with two of the Company’s long-term investments based on management’s assessment of the likelihood of near-term recovery of the investments’ value. The majority of the impairment charges relate to our investment in NantHealth common stock. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 11, “Other Comprehensive Income,” for further information regarding these impairments. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock.

Debt

Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consists of the following: June 30, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 42,662 $ 302,338 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 453,125 4,022 449,103 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 430,749 10,703 420,046 432,925 11,655 421,270 Second Lien Term Loan 167,000 8,159 158,841 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,395,874 $ 65,546 $ 1,330,328 $ 1,386,813 $ 74,433 $ 1,312,380 Less: Debt payable within one year - excluding Netsmart 21,875 462 21,413 15,638 480 15,158 Less: Debt payable within one year - Netsmart 4,351 1,891 2,460 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,369,648 $ 63,193 $ 1,306,455 $ 1,366,824 $ 72,053 $ 1,294,771 Interest expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Interest expense $ 4,668 $ 3,595 $ 9,502 $ 7,133 Amortization of discounts and debt issuance costs 3,612 3,448 7,193 6,879 Netsmart: Interest expense (1) 11,164 8,530 22,081 8,530 Amortization of discounts and debt issuance costs 846 848 1,694 848 Total interest expense $ 20,290 $ 16,421 $ 40,470 $ 23,390 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 2,156 $ 2,156 Amortization of discounts and debt issuance costs 3,278 3,108 6,524 6,216 Total interest expense related to the 1.25% Notes $ 4,356 $ 4,186 $ 8,680 $ 8,372 Allscripts Senior Secured Credit Facility As of June 30, 2017, $228.1 million under a term loan, $225.0 million under our revolving credit facility, and $0.8 million in letters of credit were outstanding under our senior secured credit facility. As of June 30, 2017, the interest rate on the borrowings under our senior secured credit facility was LIBOR plus 2.00%, which totaled 3.23%. We were in compliance with all covenants under the senior secured credit facility agreement as of June 30, 2017. As of June 30, 2017, we had $324.2 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of June 30, 2017, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. As of June 30, 2017, $430.7 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and no amounts under the Netsmart Revolving Facility (collectively, the “Credit Agreements”) were outstanding. As of June 30, 2017, the interest rate on the borrowings under the Netsmart First Lien Term Loan was Adjusted LIBO plus 4.50%, which totaled 5.80%, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.50%, which totaled 10.70%, and the interest rate on the borrowings under the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 6.05%. Netsmart was in compliance with all covenants under its Credit Agreements as of June 30, 2017. As of June 30, 2017, Netsmart had $48.5 million available, net of outstanding letters of credit of $1.5 million, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes future debt payment obligations as of June 30, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 228,125 9,375 28,125 40,625 150,000 0 0 Revolving Facility (2) 225,000 0 0 0 225,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 430,749 2,176 4,351 4,351 4,351 4,351 411,169 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,395,874 $ 11,551 $ 32,476 $ 44,976 $ 724,351 $ 4,351 $ 578,169 (1) (2)

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 (Loss) income before income taxes $ (144,018 ) $ (2,639 ) $ (152,411 ) $ 51 Income tax benefit (provision) $ 1,007 $ 503 $ 835 $ (60 ) Effective tax rate 0.7 % 19.1 % 0.5 % 117.6 % Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three and six months ended June 30, 2017, compared with the prior year comparable periods, differs primarily due to $56.5 million of valuation allowance in the six months ended June 30, 2017 for deferred taxes on investment impairment not deductible for tax until disposal of the investment. The classification of the loss at this later disposal time is yet to be determined, but likely would result in a capital loss which can only can be deductible to the extent of offsetting capital gains. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). We recorded $58.8 million of valuation allowance during the six months ended June 30, 2017 related to deferred tax assets associated with net operating loss carryforwards, credit carryforwards and other deferred tax assets not expected to be realized. Effective January 1, 2017, we adopted ASU 2016-09. The guidance in ASU 2016-09, among other things, will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled as a discrete item in the period in which they occur. In the six months ended June 30, 2017, we recorded $1.5 million of tax expense for awards in which the compensation cost recorded was higher than the tax deductions for the awards. We recorded an offsetting release of valuation allowance in the quarter of $1.5 million, the effect of which has already been included in the valuation allowance amount recorded in the six months ended June 30, 2017 noted above. ASU 2016-09 requires entities to recognize excess tax benefits, regardless of whether the tax deduction reduces taxes payable. As part of adopting the new standard, we recorded a gross cumulative effect adjustment of $5.6 million to the opening balance of accumulated deficit to create a deferred tax asset to recognize excess tax benefits not previously recorded. The net decrease to accumulated deficit was $1.8 million due to the recognition of a corresponding valuation allowance of $3.8 million. Our unrecognized income tax benefits were $12.2 million and $11.4 million as of June 30, 2017 and December 31, 2016, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: June 30, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 2,054 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 32,046 N/A 1.25% Embedded cash conversion option N/A Other liabilities 32,931 Total derivatives $ 34,100 $ 32,931 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of June 30, 2017, there were 15 forward contracts outstanding that were staggered to mature monthly starting in July 2017 and ending in June 2018. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond June 2018. As of June 30, 2017, the notional amounts of outstanding forward contracts ranged from 25 million to 120 million INR, or the equivalent of $0.4 million to $1.9 million, based on the exchange rate between the United States dollar and the INR in effect as of June 30, 2017. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three and six months ended June 30, 2017, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of June 30, 2017, we estimate that $2.1 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Foreign exchange contracts $ 434 $ 2,307 Cost of Revenue $ 255 $ 433 Selling, general and administrative expenses 194 331 Research and development $ 300 $ 510 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Foreign exchange contracts $ (141 ) $ 201 Cost of Revenue $ 27 $ (4 ) Selling, general and administrative expenses 22 (3 ) Research and development $ 37 $ (6 ) 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 1.25% Call Option $ (2,639 ) $ (10,507 ) $ 14,966 $ (41,710 ) 1.25% Embedded cash conversion option 2,631 10,577 (15,272 ) 41,970 Net (loss) gain included in other income, net $ (8 ) $ 70 $ (306 ) $ 260

Other Comprehensive Income

Other Comprehensive Income	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net (Losses) Gains on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (1) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive income (loss) before reclassifications 2,347 (85,652 ) 1,411 (81,894 ) Net losses (gains) reclassified from accumulated other comprehensive loss (2) 0 142,165 (777 ) 141,388 Net other comprehensive income 2,347 56,513 634 59,494 Balance as of June 30, 2017 (3) $ (3,681 ) $ 93 $ 1,253 $ (2,335 ) (1) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. (2) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock. (3) Net of taxes of $801 thousand for unrealized net gains on foreign exchange contract derivatives and $59 thousand for unrealized net gains on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (199 ) (18,115 ) 121 (18,193 ) Net losses reclassified from accumulated other comprehensive loss 0 0 8 8 Net other comprehensive (loss) income (199 ) (18,115 ) 129 (18,185 ) Balance as of June 30, 2016 (2) $ (4,699 ) $ (18,115 ) $ 387 $ (22,427 ) (1) (2) Net of taxes of $ Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended June 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 832 $ 0 $ 832 $ (943 ) $ 0 $ (943 ) Available for sale securities: Net loss arising during the period (10,952 ) 1 (10,951 ) (18,115 ) 0 (18,115 ) Net loss reclassified into income (1) 142,165 0 142,165 0 0 0 Net change in unrealized gains (losses) on available for sale securities 131,213 1 131,214 (18,115 ) 0 (18,115 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 434 (169 ) 265 (141 ) 55 (86 ) Net (gains) losses reclassified into income (749 ) 292 (457 ) (86 ) 34 (52 ) Net change in unrealized (losses) gains on foreign exchange contracts (315 ) 123 (192 ) (227 ) 89 (138 ) Net (loss) gain on cash flow hedges (315 ) 123 (192 ) (227 ) 89 (138 ) Other comprehensive income (loss) $ 131,730 $ 124 $ 131,854 $ (19,285 ) $ 89 $ (19,196 ) (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock. Six Months Ended June 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 2,347 $ 0 $ 2,347 $ (199 ) $ 0 $ (199 ) Available for sale securities: Net loss arising during the period (85,654 ) 2 (85,652 ) (18,115 ) 0 (18,115 ) Net loss reclassified into income (1) 142,165 0 142,165 0 0 0 Net change in unrealized gains (losses) on available for sale securities 56,511 2 56,513 (18,115 ) 0 (18,115 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,307 (896 ) 1,411 201 (80 ) 121 Net (gains) losses reclassified into income (1,274 ) 497 (777 ) 13 (5 ) 8 Net change in unrealized gains (losses) on foreign exchange contracts 1,033 (399 ) 634 214 (85 ) 129 Net gain (loss) on cash flow hedges 1,033 (399 ) 634 214 (85 ) 129 Other comprehensive income (loss) $ 59,891 $ (397 ) $ 59,494 $ (18,100 ) $ (85 ) $ (18,185 ) (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. After plaintiff’s motion to compel arbitration of the counterclaims was granted, Allscripts made a demand in arbitration where the counterclaims remain pending. Discovery in the proposed class action has now concluded. On March 31, 2016, plaintiff filed its motion for class certification.

Business Segments

Business Segments	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Business Segments	13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. As of June 30, 2017, we had seven operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the Ambulatory, Hospitals and Health Systems, previously named “Acute”, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of three separate operating segments: Population Health, FollowMyHealth ® TM Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The historical results of our Homecare TM Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Revenue: Clinical and Financial Solutions $ 286,674 $ 282,254 $ 567,129 $ 553,697 Population Health 59,736 54,026 118,798 109,081 Netsmart 78,421 44,233 151,428 44,233 Unallocated Amounts 1,260 6,008 2,211 25,068 Total revenue $ 426,091 $ 386,521 $ 839,566 $ 732,079 Gross Profit: Clinical and Financial Solutions $ 119,286 $ 121,319 $ 233,004 $ 235,340 Population Health 41,775 38,775 83,588 78,815 Netsmart 37,271 14,949 71,845 14,949 Unallocated Amounts (10,841 ) (8,359 ) (22,294 ) (10,522 ) Total gross profit $ 187,491 $ 166,684 $ 366,143 $ 318,582 Income (loss) from operations: Clinical and Financial Solutions $ 63,023 $ 67,386 $ 118,009 $ 128,224 Population Health 28,439 24,028 56,984 48,918 Netsmart 7,828 (2,399 ) 16,757 (2,399 ) Unallocated Amounts (78,186 ) (70,441 ) (159,383 ) (144,273 ) Total income from operations $ 21,104 $ 18,574 $ 32,367 $ 30,470

Supplemental Disclosures

Supplemental Disclosures	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	14. Supplemental Disclosures Restricted Cash The majority of the restricted cash balance as of June 30, 2017 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements. Six Months Ended June 30, (In thousands) 2017 2016 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 82,714 $ 90,055 Restricted cash 6,400 600 Total cash, cash equivalents and restricted cash $ 89,114 $ 90,655 Supplemental non-cash information: Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management $ 0 $ 25,543 Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 21,925 $ 8,153 Obligations incurred to purchase capitalized software or enter into capital leases $ 7,684 $ 0 Issuance of treasury stock to commercial partner $ 334 $ 0

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On July 17, 2017, Netsmart completed the acquisition of DeVero, Inc., a healthcare technology company that develops electronic medical record solutions for home healthcare and hospice, for an aggregate purchase price of approximately $51 million. The purchase price was funded through incremental borrowings under Netsmart’s debt facilities. The financial results of this company will be consolidated with our financial results starting on the date of the transaction. As of the date of this Form 10-Q, the preliminary allocation of the fair value of the consideration transferred has not yet been completed . On August 1, 2017, Allscripts Healthcare, LLC, a wholly-owned subsidiary of the Company (“Healthcare LLC”), and McKesson Corporation (“McKesson”) entered into a Purchase Agreement (the “Purchase Agreement”), pursuant to which, and subject to the terms and conditions thereof, Healthcare LLC will purchase McKesson’s Enterprise Information Solutions (EIS) Business division (the “EIS Business”), which provides certain software solutions and services to hospitals and health systems, by acquiring all of the outstanding equity interests of two indirect, wholly-owned subsidiaries of McKesson for a purchase price of $185 million, subject to adjustments for net working capital and net debt. Consummation of the acquisition is subject to customary conditions, including (i) the expiration or termination of the waiting period applicable to consummation of the acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1975, as amended, (ii) the absence of any law, order or injunction prohibiting the closing of the acquisition and (iii) the accuracy of the other party’s representations, warranties, covenants and agreements (subject to customary materiality qualifiers). Additional information about the Purchase Agreement is contained in a Current Report on Form 8-K filed with the SEC by Allscripts on August 4, 2017. We plan to fund the purchase price under the Purchase Agreement for the EIS Business using cash on hand and borrowings under our senior secured credit facilities.

Basis of Presentation and Sig22

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2017 and 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have decided to adopt the standard effective January 1, 2018 using the modified retrospective method. We have completed our assessment of our systems, available data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Through evaluation of the standard’s requirements, the Company plans to utilize several practical expedients including (i) viewing shipping and handling as a fulfillment cost versus a distinct performance obligation, and (ii) the right to invoice expedient as it relates to reimbursable expenses and transaction-related revenue activities. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscription contracts that include both software licenses and software support and maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue license recognition treatment required under the new standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Proforma Results	The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three and six months ended June 30, 2016. The consolidated statements of operations for the three and six months ended June 30, 2016 do not include any actual revenue and earnings from HealthMEDX since this acquisition was completed on October 27, 2016. The below supplemental pro forma data for the combined entity is presented under the assumption that both of these acquisitions occurred on January 1, 2015: (In thousands, except per share amounts) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 44,233 $ 44,233 Net loss $ (7,113 ) $ (7,113 ) Supplemental pro forma data for combined entity: Revenue $ 403,368 $ 804,702 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (45,494 ) $ (60,490 ) Loss per share, basic and diluted $ (0.24 ) $ (0.32 )

Fair Value Measurements and L24

Fair Value Measurements and Long-term Investments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet June 30, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 63,450 $ 0 $ 0 $ 63,450 $ 149,100 $ 0 $ 0 $ 149,100 Non-marketable convertible note Other assets 0 0 1,152 1,152 0 0 1,156 1,156 1.25% Call Option Other assets 0 0 32,046 32,046 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (32,931 ) (32,931 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 2,054 0 2,054 0 1,021 0 1,021 Total $ 63,450 $ 2,054 $ 267 $ 65,771 $ 149,100 $ 1,021 $ 577 $ 150,698
Schedule Of Long-term Equity And Cost Method Investments Table [Text Block]	The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at June 30, 2017 Investment June 30, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 3,693 $ 2,436 Cost method investments 6 31,284 25,284 26,041 Total equity investments 9 $ 32,942 $ 28,977 $ 28,477 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 988 $ 1,061 $ 2,113 $ 2,230 Client services 993 1,138 2,565 2,628 Total cost of revenue 1,981 2,199 4,678 4,858 Selling, general and administrative expenses 7,050 6,342 10,600 11,508 Research and development 2,120 2,119 4,709 4,695 Total stock-based compensation expense $ 11,151 $ 10,660 $ 19,987 $ 21,061
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 128 $ 11.93 1,897 $ 12.38 Performance-based restricted stock units with a service condition 0 $ 0.00 572 $ 11.93 Market-based restricted stock units with a service condition 41 $ 12.49 613 $ 13.34 169 $ 12.06 3,082 $ 12.48
Netsmart [Member]
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 10 $ 25 $ (25 ) $ 25 Client services 13 37 (68 ) 37 Total cost of revenue 23 62 (93 ) 62 Selling, general and administrative expenses 478 1,328 (2,859 ) 1,328 Research and development 15 36 (76 ) 36 Total stock-based compensation expense (benefit) $ 516 $ 1,426 $ (3,028 ) $ 1,426

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2017 2016 2017 2016 Basic Loss per Common Share: Net loss $ (143,011 ) $ (2,136 ) $ (151,576 ) $ (9 ) Less: Net loss (income) attributable to non-controlling interests 264 87 (189 ) 9 Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,963 ) (8,153 ) (21,925 ) (8,153 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (153,710 ) $ (10,202 ) $ (173,690 ) $ (8,153 ) Weighted-average common shares outstanding 181,193 186,792 180,981 187,676 Basic Loss per Common Share $ (0.85 ) $ (0.05 ) $ (0.96 ) $ (0.04 ) Diluted Loss per Common Share: Net loss $ (143,011 ) $ (2,136 ) $ (151,576 ) $ (9 ) Less: Net loss (income) attributable to non-controlling interests 264 87 (189 ) 9 Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,963 ) (8,153 ) (21,925 ) (8,153 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (153,710 ) $ (10,202 ) $ (173,690 ) $ (8,153 ) Weighted-average common shares outstanding 181,193 186,792 180,981 187,676 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 181,193 186,792 180,981 187,676 Diluted Loss per Common Share $ (0.85 ) $ (0.05 ) $ (0.96 ) $ (0.04 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,652 25,210 26,668 25,227

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: June 30, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 628,082 $ (375,531 ) $ 252,551 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 813,643 (446,244 ) 367,399 813,021 (430,960 ) 382,061 Total $ 1,441,725 $ (821,775 ) $ 619,950 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,929,283 1,924,052 Total $ 2,008,283 $ 2,003,052
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 Other additions 40 47 4,503 4,590 Foreign exchange translation 641 0 0 641 Balance as of June 30, 2017 $ 844,518 $ 404,922 $ 679,843 $ 1,929,283

Asset and Long-term Investmen28

Asset and Long-term Investment Impairment Charges (Tables)	6 Months Ended
	Jun. 30, 2017
Asset And Long Term Investment Impairment Charges [Abstract]
Asset and Long-term Investment Impairment Charges	We incurred the following asset and long-term investment impairment charges: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Asset impairment charges $ 0 $ 0 $ 0 $ 4,650 Impairment of long-term investments $ 144,590 $ 0 $ 144,590 $ 0

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consists of the following: June 30, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 42,662 $ 302,338 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 453,125 4,022 449,103 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 430,749 10,703 420,046 432,925 11,655 421,270 Second Lien Term Loan 167,000 8,159 158,841 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,395,874 $ 65,546 $ 1,330,328 $ 1,386,813 $ 74,433 $ 1,312,380 Less: Debt payable within one year - excluding Netsmart 21,875 462 21,413 15,638 480 15,158 Less: Debt payable within one year - Netsmart 4,351 1,891 2,460 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,369,648 $ 63,193 $ 1,306,455 $ 1,366,824 $ 72,053 $ 1,294,771
Interest Expense	Interest expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Interest expense $ 4,668 $ 3,595 $ 9,502 $ 7,133 Amortization of discounts and debt issuance costs 3,612 3,448 7,193 6,879 Netsmart: Interest expense (1) 11,164 8,530 22,081 8,530 Amortization of discounts and debt issuance costs 846 848 1,694 848 Total interest expense $ 20,290 $ 16,421 $ 40,470 $ 23,390 (1) Includes interest expense related to capital leases.
Summary of Future Debt Payment Obligations	The following table summarizes future debt payment obligations as of June 30, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 228,125 9,375 28,125 40,625 150,000 0 0 Revolving Facility (2) 225,000 0 0 0 225,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 430,749 2,176 4,351 4,351 4,351 4,351 411,169 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,395,874 $ 11,551 $ 32,476 $ 44,976 $ 724,351 $ 4,351 $ 578,169 (1) (2)
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 1.25% Notes	Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 2,156 $ 2,156 Amortization of discounts and debt issuance costs 3,278 3,108 6,524 6,216 Total interest expense related to the 1.25% Notes $ 4,356 $ 4,186 $ 8,680 $ 8,372

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 (Loss) income before income taxes $ (144,018 ) $ (2,639 ) $ (152,411 ) $ 51 Income tax benefit (provision) $ 1,007 $ 503 $ 835 $ (60 ) Effective tax rate 0.7 % 19.1 % 0.5 % 117.6 %

Derivative Financial Instrume31

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: June 30, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 2,054 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 32,046 N/A 1.25% Embedded cash conversion option N/A Other liabilities 32,931 Total derivatives $ 34,100 $ 32,931 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 Foreign exchange contracts $ 434 $ 2,307 Cost of Revenue $ 255 $ 433 Selling, general and administrative expenses 194 331 Research and development $ 300 $ 510 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Foreign exchange contracts $ (141 ) $ 201 Cost of Revenue $ 27 $ (4 ) Selling, general and administrative expenses 22 (3 ) Research and development $ 37 $ (6 )
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 1.25% Call Option $ (2,639 ) $ (10,507 ) $ 14,966 $ (41,710 ) 1.25% Embedded cash conversion option 2,631 10,577 (15,272 ) 41,970 Net (loss) gain included in other income, net $ (8 ) $ 70 $ (306 ) $ 260

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net (Losses) Gains on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (1) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive income (loss) before reclassifications 2,347 (85,652 ) 1,411 (81,894 ) Net losses (gains) reclassified from accumulated other comprehensive loss (2) 0 142,165 (777 ) 141,388 Net other comprehensive income 2,347 56,513 634 59,494 Balance as of June 30, 2017 (3) $ (3,681 ) $ 93 $ 1,253 $ (2,335 ) (1) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. (2) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock. (3) Net of taxes of $801 thousand for unrealized net gains on foreign exchange contract derivatives and $59 thousand for unrealized net gains on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (199 ) (18,115 ) 121 (18,193 ) Net losses reclassified from accumulated other comprehensive loss 0 0 8 8 Net other comprehensive (loss) income (199 ) (18,115 ) 129 (18,185 ) Balance as of June 30, 2016 (2) $ (4,699 ) $ (18,115 ) $ 387 $ (22,427 ) (1) (2) Net of taxes of $
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended June 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 832 $ 0 $ 832 $ (943 ) $ 0 $ (943 ) Available for sale securities: Net loss arising during the period (10,952 ) 1 (10,951 ) (18,115 ) 0 (18,115 ) Net loss reclassified into income (1) 142,165 0 142,165 0 0 0 Net change in unrealized gains (losses) on available for sale securities 131,213 1 131,214 (18,115 ) 0 (18,115 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 434 (169 ) 265 (141 ) 55 (86 ) Net (gains) losses reclassified into income (749 ) 292 (457 ) (86 ) 34 (52 ) Net change in unrealized (losses) gains on foreign exchange contracts (315 ) 123 (192 ) (227 ) 89 (138 ) Net (loss) gain on cash flow hedges (315 ) 123 (192 ) (227 ) 89 (138 ) Other comprehensive income (loss) $ 131,730 $ 124 $ 131,854 $ (19,285 ) $ 89 $ (19,196 ) (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock. Six Months Ended June 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 2,347 $ 0 $ 2,347 $ (199 ) $ 0 $ (199 ) Available for sale securities: Net loss arising during the period (85,654 ) 2 (85,652 ) (18,115 ) 0 (18,115 ) Net loss reclassified into income (1) 142,165 0 142,165 0 0 0 Net change in unrealized gains (losses) on available for sale securities 56,511 2 56,513 (18,115 ) 0 (18,115 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,307 (896 ) 1,411 201 (80 ) 121 Net (gains) losses reclassified into income (1,274 ) 497 (777 ) 13 (5 ) 8 Net change in unrealized gains (losses) on foreign exchange contracts 1,033 (399 ) 634 214 (85 ) 129 Net gain (loss) on cash flow hedges 1,033 (399 ) 634 214 (85 ) 129 Other comprehensive income (loss) $ 59,891 $ (397 ) $ 59,494 $ (18,100 ) $ (85 ) $ (18,185 ) (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock.

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2017 2016 2017 2016 Revenue: Clinical and Financial Solutions $ 286,674 $ 282,254 $ 567,129 $ 553,697 Population Health 59,736 54,026 118,798 109,081 Netsmart 78,421 44,233 151,428 44,233 Unallocated Amounts 1,260 6,008 2,211 25,068 Total revenue $ 426,091 $ 386,521 $ 839,566 $ 732,079 Gross Profit: Clinical and Financial Solutions $ 119,286 $ 121,319 $ 233,004 $ 235,340 Population Health 41,775 38,775 83,588 78,815 Netsmart 37,271 14,949 71,845 14,949 Unallocated Amounts (10,841 ) (8,359 ) (22,294 ) (10,522 ) Total gross profit $ 187,491 $ 166,684 $ 366,143 $ 318,582 Income (loss) from operations: Clinical and Financial Solutions $ 63,023 $ 67,386 $ 118,009 $ 128,224 Population Health 28,439 24,028 56,984 48,918 Netsmart 7,828 (2,399 ) 16,757 (2,399 ) Unallocated Amounts (78,186 ) (70,441 ) (159,383 ) (144,273 ) Total income from operations $ 21,104 $ 18,574 $ 32,367 $ 30,470

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule Of Supplemental Disclosures [Table Text Block]	The majority of the restricted cash balance as of June 30, 2017 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements. Six Months Ended June 30, (In thousands) 2017 2016 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 82,714 $ 90,055 Restricted cash 6,400 600 Total cash, cash equivalents and restricted cash $ 89,114 $ 90,655 Supplemental non-cash information: Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management $ 0 $ 25,543 Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 21,925 $ 8,153 Obligations incurred to purchase capitalized software or enter into capital leases $ 7,684 $ 0 Issuance of treasury stock to commercial partner $ 334 $ 0

Basis of Presentation and Sig35

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2017	Jun. 30, 2017
ASU 2016-09 [Member]
Summary Of Significant Accounting Policy [Line Items]
Decrease in accumulated deficit due to the recognition of excess tax benefit after valuation allowance	$ 1.8	$ 1.8

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 27, 2016	Apr. 19, 2016	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill				$ 1,929,283	$ 1,924,052
Contribution and investment agreement date				Mar. 20, 2016
Homecare Business [Member]
Business Acquisition [Line Items]
Escrow deposit related to the integration of homecare business		$ 15,000		$ 12,800
Escrow deposit period		5 years
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date				Apr. 19, 2016
HealthMEDX, LLC [Member]
Business Acquisition [Line Items]
Date of acquisition	Oct. 27, 2016
Business combination, aggregate consideration	$ 39,200
Business combination, adjustment of fair value of liability			$ 100
Increase in goodwill from subsequent adjustment of liability			$ 100
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Asset purchase agreement date			Mar. 31, 2017
Aggregate cash consideration to acquire intellectual property, certain contractual relationships and certain associates			$ 4,000
Business combination, estimated consideration payable			700
Contingent consideration, fair value				$ 500
Goodwill			$ 4,400

Pro forma Results (Detail)

Pro forma Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Netsmart [Member]
Business Acquisition [Line Items]
Revenue	$ 44,233	$ 44,233
Net loss	(7,113)	(7,113)
Combined Entity [Member]
Business Acquisition [Line Items]
Revenue	403,368	804,702
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (45,494)	$ (60,490)
Loss per share, basic and diluted	$ (0.24)	$ (0.32)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	$ 63,450	$ 149,100
Prepaid expenses and other current assets	113,563	102,551
Total	65,771	150,698
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	2,054	1,021
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(32,931)	(17,659)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	32,046	17,080
Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	1,152	1,156
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	63,450	149,100
Total	63,450	149,100
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 1 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	2,054	1,021
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	2,054	1,021
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	267	577
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(32,931)	(17,659)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	32,046	17,080
Level 3 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 1,152	$ 1,156

Summary of Long-term Equity Inv

Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		6 Months Ended
		Jun. 30, 2017USD ($)Investment	Dec. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	3
Cost method investments, Number of Investees | Investment		6
Total equity investments, Number of Investees | Investment		9
Equity method investments, Original Investment	[1]	$ 1,658
Cost method investments, Original Investment		31,284
Total equity investments, Original Investment		32,942
Equity method investments, Carrying Value		3,693	$ 2,436
Cost method investments, Carrying Value		25,284	26,041
Total equity investments, Carrying Value		$ 28,977	$ 28,477
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and L40

Fair Value Measurements and Long-term Investments - Additional Information (Detail) $ in Millions	3 Months Ended
	Jun. 30, 2017USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other-than-temporary impairment charges on available for sale marketable securities	$ 142.2
Available for sale marketable securities cost basis	$ 205.6
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%
Equity Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other-than-temporary impairment charges on cost method equity investments	$ 2.1
Aggregate carrying value of cost method investments prior to impairment charges	$ 2.1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Nov. 17, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0	$ 0	$ 0
Stock options granted	0	0	0	0
Share issued, exercise of options and release of stock awards			1,100,000		1,500,000
Shares settled for tax withholding			552,000	564,000
Common stock repurchased, amount			$ 12,077,000	$ 52,075,000
Netsmart [Member]
Class Of Stock [Line Items]
Liability for outstanding awards	$ 2,800,000		$ 2,800,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model	$ 0.15		$ 0.15		$ 1
November 2016 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 200,000,000
Common stock repurchased, shares	1,000,000		1,000,000
Common stock repurchased, amount	$ 12,100,000		$ 12,100,000

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 11,151	$ 10,660	$ 19,987	$ 21,061
Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	516	1,426	(3,028)	1,426
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,981	2,199	4,678	4,858
Cost of revenue [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	23	62	(93)	62
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	988	1,061	2,113	2,230
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	10	25	(25)	25
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	993	1,138	2,565	2,628
Cost of revenue [Member] | Client services [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	13	37	(68)	37
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	7,050	6,342	10,600	11,508
Selling, General and Administrative Expenses [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	478	1,328	(2,859)	1,328
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,120	2,119	4,709	4,695
Research and development [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	$ 15	$ 36	$ (76)	$ 36

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	169	3,082
Weighted-Average Grant Date Fair Value, granted	$ 12.06	$ 12.48
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	128	1,897
Weighted-Average Grant Date Fair Value, granted	$ 11.93	$ 12.38
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	572
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 11.93
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	41	613
Weighted-Average Grant Date Fair Value, granted	$ 12.49	$ 13.34

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Basic Loss per Common Share:
Net loss	$ (143,011)	$ (2,136)	$ (151,576)	$ (9)
Less: Net loss (income) attributable to non-controlling interests	264	87	(189)	9
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,963)	(8,153)	(21,925)	(8,153)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (153,710)	$ (10,202)	$ (173,690)	$ (8,153)
Weighted-average common shares outstanding	181,193	186,792	180,981	187,676
Basic Loss per Common Share	$ (0.85)	$ (0.05)	$ (0.96)	$ (0.04)
Diluted Loss per Common Share:
Net loss	$ (143,011)	$ (2,136)	$ (151,576)	$ (9)
Less: Net loss (income) attributable to non-controlling interests	264	87	(189)	9
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,963)	(8,153)	(21,925)	(8,153)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (153,710)	$ (10,202)	$ (173,690)	$ (8,153)
Weighted-average common shares outstanding	181,193	186,792	180,981	187,676
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	181,193	186,792	180,981	187,676
Diluted Loss per Common Share	$ (0.85)	$ (0.05)	$ (0.96)	$ (0.04)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	26,652	25,210	26,668	25,227

Goodwill and Intangible Asset46

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,441,725	$ 1,440,840
Accumulated Amortization	(821,775)	(778,437)
Intangible Assets, Net	619,950	662,403
Registered trademarks	79,000	79,000
Goodwill	1,929,283	1,924,052
Total	2,008,283	2,003,052
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	628,082	627,819
Accumulated Amortization	(375,531)	(347,477)
Intangible Assets, Net	252,551	280,342
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	813,643	813,021
Accumulated Amortization	(446,244)	(430,960)
Intangible Assets, Net	$ 367,399	$ 382,061

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Line Items]
Goodwill	$ 1,924,052
Other additions	4,590
Foreign exchange translation	641
Goodwill, net	1,929,283
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	843,837
Other additions	40
Foreign exchange translation	641
Goodwill, net	844,518
Population Health [Member]
Goodwill [Line Items]
Goodwill	404,875
Other additions	47
Foreign exchange translation	0
Goodwill, net	404,922
Netsmart [Member]
Goodwill [Line Items]
Goodwill	675,340
Other additions	4,503
Foreign exchange translation	0
Goodwill, net	$ 679,843

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Asset and Long-term Investmen49

Asset and Long-term Investment Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Asset And Long Term Investment Impairment Charges [Abstract]
Asset impairment charges	$ 0	$ 0	$ 0	$ 4,650
Impairment of long-term investments	$ 144,590	$ 0	$ 144,590	$ 0

Asset and Long-term Investmen50

Asset and Long-term Investment Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges	$ 0	$ 0		$ 0	$ 4,650
Other charges			$ 400
Other than temporary non-cash impairment charges on long-term Investments	$ 144,590	$ 0		$ 144,590	$ 0
Capitalized Software Development Projects [Member]
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges			2,200
Cost Method Equity Investments [Member]
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges			$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Principal Balance	$ 1,395,874		$ 1,386,813
Unamortized Discount and Debt Issuance Costs	65,546		74,433
Net Carrying Amount	1,330,328		1,312,380
Principal Balance, Current	21,875		15,638
Unamortized Discount and Debt Issuance Costs, Current	462		480
Net Carrying Amount, Current	21,413		15,158
Principal Balance, Noncurrent	1,369,648		1,366,824
Unamortized Discount and Debt Issuance Costs, Noncurrent	63,193		72,053
Net Carrying Amount, Noncurrent	1,306,455		1,294,771
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	4,351		4,351
Unamortized Discount and Debt Issuance Costs, Current	1,891		1,900
Net Carrying Amount, Current	2,460		2,451
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	42,662		49,186
Net Carrying Amount	302,338		295,814
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	453,125		441,875
Unamortized Discount and Debt Issuance Costs	4,022		4,691
Net Carrying Amount	449,103		437,184
Netsmart Non-Recourse Debt First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	430,749		432,925
Unamortized Discount and Debt Issuance Costs	10,703		11,655
Net Carrying Amount	420,046		421,270
Netsmart Non-Recourse Debt Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		167,000
Unamortized Discount and Debt Issuance Costs	8,159		8,901
Net Carrying Amount	158,841		158,099
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	0		13
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 0		$ 13
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Debt Instrument [Line Items]
Total interest expense		$ 20,290	$ 16,421	$ 40,470	$ 23,390
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense		4,668	3,595	9,502	7,133
Amortization of discounts and debt issuance costs		3,612	3,448	7,193	6,879
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		846	848	1,694	848
Interest expense	[1]	$ 11,164	$ 8,530	$ 22,081	$ 8,530
[1]	Includes interest expense related to capital leases.

Interest Expense Related to 1.2

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078	$ 2,156	$ 2,156
Amortization of discounts and debt issuance costs	3,278	3,108	6,524	6,216
Total interest expense related to the 1.25% Notes	$ 4,356	$ 4,186	$ 8,680	$ 8,372

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)		6 Months Ended
		Jun. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,395,874,000		$ 1,386,813,000
Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		6.05%
LIBOR Rate [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		4.75%
Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	[1]	$ 228,125,000
Allscripts Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		225,000,000
Letters of credit outstanding		800,000
Credit facility, amount available		$ 324,200,000
Allscripts Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		3.23%
Allscripts Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		2.00%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 345,000,000	[2]	$ 345,000,000
Interest rate		1.25%
Netsmart First Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 0
Letters of credit outstanding		1,500,000
Credit facility, amount available		48,500,000
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 430,700,000
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		10.70%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 167,000,000
Netsmart Second Lien Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		9.50%
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 430,749,000
Debt instrument, interest rate, effective percentage		5.80%
Netsmart First Lien Term Loan [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		4.50%
[1]	Assumes no additional borrowings after June 30, 2017, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.
[2]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Debt Payment

Summary of Future Debt Payment Obligations (Detail) - USD ($) $ in Thousands		Jun. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Total		$ 1,395,874		$ 1,386,813
Remainder of 2017		11,551
2,018		32,476
2,019		44,976
2,020		724,351
2,021		4,351
Thereafter		578,169
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	$ 345,000
Remainder of 2017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
2,021	[1]	0
Thereafter	[1]	0
Term Loan [Member]
Debt Instrument [Line Items]
Total	[2]	228,125
Remainder of 2017	[2]	9,375
2,018	[2]	28,125
2,019	[2]	40,625
2,020	[2]	150,000
2,021	[2]	0
Thereafter	[2]	0
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		430,749
Remainder of 2017		2,176
2,018		4,351
2,019		4,351
2,020		4,351
2,021		4,351
Thereafter		411,169
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000
Remainder of 2017		0
2,018		0
2,019		0
2,020		0
2,021		0
Thereafter		167,000
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	[2]	225,000
Remainder of 2017	[2]	0
2,018	[2]	0
2,019	[2]	0
2,020	[2]	225,000
2,021	[2]	0
Thereafter	[2]	$ 0
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.
[2]	Assumes no additional borrowings after June 30, 2017, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Summary of Future Debt Paymen56

Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2017
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
(Loss) income before income taxes	$ (144,018)	$ (2,639)	$ (152,411)	$ 51
Income tax benefit (provision)	$ 1,007	$ 503	$ 835	$ (60)
Effective tax rate	0.70%	19.10%	0.50%	117.60%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance		$ 56.5
Cumulative operating income loss period considered		3 years
Unrecognized income tax benefits		$ 12.2	$ 11.4
ASU 2016-09 [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax expense on compensation cost	$ 1.5
Change in valuation allowance from offsetting release	(1.5)
Cumulative effect adjustment on accumulated deficit, gross	5.6
Decrease in accumulated deficit due to the recognition of excess tax benefit after valuation allowance	1.8	1.8
Valuation allowance recognized	$ 3.8
Valuation Allowance of Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance related to deferred tax assets from operating loss carryforwards		$ 58.8

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 34,100	$ 18,101
Derivative liability, fair value	32,931	17,659
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	2,054	1,021
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	32,046	17,080
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 32,931	$ 17,659

Derivative Financial Instrume60

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2017USD ($)Derivative	Jun. 30, 2017USD ($)Derivative	Jun. 30, 2017INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	15	15	15
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 0	$ 0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	2,100,000	$ 2,100,000
Estimated period of unrealized gains included in AOCI reclassified into income		12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature		Jul. 31, 2017
Derivative notional amount outstanding	400,000	$ 400,000	₨ 25,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature		Jun. 30, 2018
Derivative notional amount outstanding	$ 1,900,000	$ 1,900,000	₨ 120,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option				$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 434	$ (141)	$ 2,307	$ 201
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	255	27	433	(4)
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	194	22	331	(3)
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 300	$ 37	$ 510	$ (6)

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ (8)	$ 70	$ (306)	$ 260
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	(2,639)	(10,507)	14,966	(41,710)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ 2,631	$ 10,577	$ (15,272)	$ 41,970

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,232,466
Total other comprehensive income (loss)	$ 131,854	$ (19,196)	59,494	$ (18,185)
Balance at the end of the period	1,124,565		1,124,565
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(6,028)	(4,500)
Other comprehensive income (loss) before reclassifications			2,347	(199)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive income (loss)			2,347	(199)
Balance at the end of the period	(3,681)	(4,699)	(3,681)	(4,699)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(56,420)	0
Other comprehensive income (loss) before reclassifications			(85,652)	(18,115)
Net losses (gains) reclassified from accumulated other comprehensive loss			142,165	0
Total other comprehensive income (loss)			56,513	(18,115)
Balance at the end of the period	93	(18,115)	93	(18,115)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			619	258
Other comprehensive income (loss) before reclassifications			1,411	121
Net losses (gains) reclassified from accumulated other comprehensive loss			(777)	8
Total other comprehensive income (loss)			634	129
Balance at the end of the period	1,253	387	1,253	387
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(61,829)	(4,242)
Other comprehensive income (loss) before reclassifications			(81,894)	(18,193)
Net losses (gains) reclassified from accumulated other comprehensive loss			141,388	8
Total other comprehensive income (loss)			59,494	(18,185)
Balance at the end of the period	$ (2,335)	$ (22,427)	$ (2,335)	$ (22,427)

Components of Accumulated Oth64

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 59	$ 61
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 801	$ 402	$ 251	$ 166

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 832	$ (943)	$ 2,347	$ (199)
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	131,213	(18,115)	56,511	(18,115)
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(315)	(227)	1,033	214
Other comprehensive (loss) income, Before-Tax Amount	131,730	(19,285)	59,891	(18,100)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive (loss) income, Tax Effect	124	89	(397)	(85)
Foreign currency translation adjustments, Net	832	(943)	2,347	(199)
Other comprehensive (loss) income, Net	131,854	(19,196)	59,494	(18,185)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Available for sale securities, net loss arising during the period, Before-Tax Amount	(10,952)	(18,115)	(85,654)	(18,115)
Available for sale securities, net loss reclassified into income, Before-Tax Amount	142,165	0	142,165	0
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	131,213	(18,115)	56,511	(18,115)
Available for sale securities, net loss arising during the period, Tax Effect	1	0	2	0
Available for sale securities, net loss reclassified into income, Tax Effect	0	0	0	0
Net change in unrealized gains (losses) on available for sale securities, Tax Effect	1	0	2	0
Available for sale securities, net loss arising during the period, Net	(10,951)	(18,115)	(85,652)	(18,115)
Available for sale securities, net loss reclassified into income, Net	142,165	0	142,165	0
Net change in unrealized gains (losses) on available for sale securities, Net	131,214	(18,115)	56,513	(18,115)
Other comprehensive (loss) income, Net			56,513	(18,115)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(315)	(227)	1,033	214
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	123	89	(399)	(85)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	(192)	(138)	634	129
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	434	(141)	2,307	201
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(749)	(86)	(1,274)	13
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(315)	(227)	1,033	214
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Tax Effect	(169)	55	(896)	(80)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	292	34	497	(5)
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	123	89	(399)	(85)
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Net	265	(86)	1,411	121
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(457)	(52)	(777)	8
Derivatives qualifying as cash flow hedges, net gain (loss), Net	$ (192)	$ (138)	634	129
Other comprehensive (loss) income, Net			$ 634	$ 129

Contingencies - Additional Info

Contingencies - Additional Information (Detail)	May 01, 2012$ / Violation
Pending Litigation [Member] | Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA	500

Business Segments - Additional

Business Segments - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Number of operating segments	7

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 426,091	$ 386,521	$ 839,566	$ 732,079
Gross Profit	187,491	166,684	366,143	318,582
Income from operations	21,104	18,574	32,367	30,470
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	1,260	6,008	2,211	25,068
Gross Profit	(10,841)	(8,359)	(22,294)	(10,522)
Income from operations	(78,186)	(70,441)	(159,383)	(144,273)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	286,674	282,254	567,129	553,697
Gross Profit	119,286	121,319	233,004	235,340
Income from operations	63,023	67,386	118,009	128,224
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	59,736	54,026	118,798	109,081
Gross Profit	41,775	38,775	83,588	78,815
Income from operations	28,439	24,028	56,984	48,918
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	78,421	44,233	151,428	44,233
Gross Profit	37,271	14,949	71,845	14,949
Income from operations	$ 7,828	$ (2,399)	$ 16,757	$ (2,399)

Supplemental Disclosures - Addi

Supplemental Disclosures - Additional Information (Detail)	Jun. 30, 2017LetterOfCredit
Netsmart [Member]
Schedule Of Supplemental Disclosures [Line Items]
Number of letter of credit maintained	2

Summary of Reconciliation of Ca

Summary of Reconciliation of Cash and Cash Equivalent, Restricted Cash and Supplemental Non-Cash Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 82,714	$ 90,055	$ 82,714	$ 90,055	$ 95,607
Restricted cash	6,400	600	6,400	600	1,003
Total cash, cash equivalents and restricted cash	89,114	90,655	89,114	90,655	$ 96,610	$ 116,873
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	$ 10,963	$ 8,153	21,925	8,153
Obligations incurred to purchase capitalized software or enter into capital leases			7,684	0
Issuance of treasury stock to commercial partner			334	0
Netsmart Inc Management
Supplemental non-cash information:
Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management			$ 0	$ 25,543

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Thousands	Aug. 03, 2017shares	Jul. 17, 2017USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Aug. 01, 2017USD ($)Subsidiary
Subsequent Event [Line Items]
Cash paid for business acquisitions			$ 3,975	$ 905,540
Subsequent Event [Member] | NantHealth, Inc. [Member]
Subsequent Event [Line Items]
Number of shares as consideration for asset purchase agreement | shares	15,000,000
Subsequent Event [Member] | McKesson Corporation [Member]
Subsequent Event [Line Items]
Number of wholly owned subsidiaries in which outstanding equity interest acquired | Subsidiary					2
Purchase price net of adjustments					$ 185,000
Subsequent Event [Member] | Netsmart [Member] | DeVero, Inc. [Member]
Subsequent Event [Line Items]
Cash paid for business acquisitions		$ 51,000